New NIH-funded memory drug moves into Phase 1 clinical study

Wednesday, December 30, 2015
NIH Default Logo

Tetra Discovery Partners, supported by the NIH Blueprint Neurotherapeutics (BPN) program since the program’s inception, is moving an experimental new drug, that may improve memory, into a Phase 1 safety trial. The compound is a first in class phosphodiesterase 4D negative allosteric modulator.  It inhibits an enzyme thought to interfere with long-term memory formation and is designed to treat memory loss in early-to-moderate Alzheimer’s disease patients.  Read more about Tetra Discovery Partners.  The compound is the first drug funded by the BPN to move into a Phase 1 Clinical Trial.

View the full article.

Was this page helpful?
Form Approved OMB# 0925-0648 Exp. Date 05/31/2021